Table 3 Summary of responses to treatment

From: Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

 

N = 55 (%)

Best response (IMWG)—no. (%)

 PR or better [95% CI]

51 (93) [92–98]

 VGPR or better [95% CI]

25 (45) [32–59]

 CRa

17 (31)

 VGPR

8 (15)

 PR

26 (47)

  1. aAll patients with CR achieved stringent CR.
Back to article page